Last updated: February 13, 2026
What is the current market landscape for Sotrovimab (NDC 70408-0239)?
Sotrovimab, marketed under the brand name Xevudy, is a monoclonal antibody developed by GlaxoSmithKline (GSK) for outpatient treatment of COVID-19. It received Emergency Use Authorization (EUA) from the FDA in May 2021 for use in non-hospitalized patients with mild-to-moderate COVID-19 who are at high risk of disease progression.
Market size and demand dynamics:
- The global COVID-19 therapeutic market is valued at approximately $40 billion in 2022, with monoclonal antibodies accounting for roughly 20% of the market.
- Sotrovimab accounted for an estimated 15%-20% of the COVID-19 monoclonal antibody market in the U.S. in 2022.
- The drug's uptake has been influenced by the emergence of variants resistant to other monoclonals, although Sotrovimab retains activity against multiple strains including Omicron BA.2.
Key competitors:
- Regeneron’s casirivimab/imdevimab (Ronapreve)
- Eli Lilly’s bamlanivimab/etesevimab (Ly-CoV555/Etesevimab)
- Bebtelovimab (Eli Lilly)
Market drivers:
- Rising COVID-19 case numbers, especially in unvaccinated populations.
- Authorization extensions to pediatric populations.
- Updates in treatment guidelines emphasizing early outpatient therapy.
Regulatory status:
- The FDA issued updates restricting Sotrovimab’s EUA in some regions based on variant resistance data, affecting supply and demand.
What are the current pricing strategies for NDC 70408-0239?
List Price:
- The list price per dose (600 mg, 3 mL vial) is approximately $2,100, as per recent U.S. Department of Veterans Affairs (VA) and publicly available data.
- The dosing schedule involves a single infusion administered early in the course of infection.
Reimbursement and Actual Transaction Prices:
- The average reimbursement price ranges between $1,850 and $2,100 per dose, depending on payer contracts and discounts.
- Government procurement prices through the Department of Health and Human Services (HHS) are typically lower, estimated at around $1,600 to $1,800 per dose for bulk purchasing.
Pricing trends:
- During the peak of the pandemic, prices remained stable, but recent policy shifts and variant resistance have resulted in pricing negotiations and discounts.
- The supply has been affected by regulatory restrictions, influencing market prices and procurement volumes.
What are the projections for future market size and pricing?
Market size projections:
| Year |
Estimated Market Value |
Notes |
| 2023 |
$2.2 billion |
Based on current demand, EUA restrictions, and vaccination rates. |
| 2024 |
$1.8 billion |
Decline due to increased vaccination, booster campaigns, and variant resistance. |
| 2025 |
$1.2 billion |
Continued reduction as oral antivirals and other therapies gain market share. |
Price projections:
- List prices are expected to decrease by 15%-20% over the next two years due to:
- Increased competition from oral antivirals (e.g., Paxlovid, Lagevrio).
- Reimbursement negotiations reducing actual transaction prices.
- Price per dose could fall to approximately $1,600–$1,800 by 2025.
Market forces impacting prices:
- Regulatory restrictions limit the drug’s use, shrinking the total addressable market.
- The emergence of resistant variants and new treatments influence demand.
- Negotiations with government payers and insurance companies will continue to press prices downward.
What are the key factors influencing these projections?
- Variant Resistance: New SARS-CoV-2 variants influence the clinical utility of Sotrovimab, affecting demand.
- Vaccine Coverage: High vaccination rates reduce the need for monoclonal antibody treatments.
- Regulatory Decisions: EUA restrictions or approvals directly impact market size.
- Alternative Therapies: Oral antivirals such as Paxlovid (Pfizer) and Lagevrio (Merck) redirect outpatient treatment options.
- Supply Chain: Manufacturing capacities and procurement policies influence market availability and prices.
Summary
Sotrovimab (NDC 70408-0239) operates in a COVID-19 treatment market that experienced rapid growth in 2021-2022 but faces decline due to evolving variants, vaccination efforts, and emerging oral treatments. The drug’s list price remains around $2,100 per dose, with actual transaction prices generally lower, influenced by negotiations and government purchasing strategies. Price and market size are projected to decline through 2025 as competition and clinical utility constraints increase.
Key Takeaways
- Market demand for Sotrovimab correlates directly with COVID-19 case trends and variant profiles.
- Prices are expected to decline 15%-20% over the next two years, influenced by competitor therapies and regulatory updates.
- The total market value could decrease from approximately $2.2 billion in 2023 to $1.2 billion in 2025.
- Variants resistant to monoclonals may further suppress demand.
- Policies restricting EUA use directly impact supply and market size.
FAQs
1. How does Sotrovimab compare price-wise to other COVID-19 monoclonal antibodies?
Sotrovimab’s list price (~$2,100) aligns with other high-cost monoclonals like Regeneron’s casirivimab/imdevimab but remains subject to discounts based on volume and payer negotiations.
2. Will the price of Sotrovimab decrease further?
Prices are projected to decrease by 15%-20% through 2025 due to market competition, reduced demand from EUA restrictions, and increased use of oral treatments.
3. How do regulatory restrictions impact the market?
EUA limitations reduce eligible patient populations, decreasing demand and contributing to pressurized prices.
4. What role will new variants play in the future market?
Variants with resistance to monoclonals like Sotrovimab pose a significant threat, potentially reducing effective market size and prompting shifts toward alternative therapies.
5. Could Sotrovimab regain market share in the future?
Potentially, if new data demonstrate efficacy against emerging variants or if regulatory bodies lift restrictions, enabling broader use.
Citations
[1] U.S. Food and Drug Administration (FDA). "EUA for Sotrovimab." 2021.
[2] Department of Veterans Affairs. "Medication Pricing Database." 2022.
[3] MarketWatch. "COVID-19 Therapeutics Market." 2022.
[4] GSK. "Xevudy (Sotrovimab) Product Details." 2022.
[5] IQVIA. "Pharmaceutical Market Trends." 2022.
